Analyst consensus rating
Aquestive Therapeutics Analyst Rating: Strong Buy
Direct answer
Aquestive Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.33.
Forecast evidence checked September 8, 2026.
Get free Aquestive Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.21
- Average price target
- $9.33
- High price target
- $11.00
- Low price target
- $6.00
- Low target gap
- +15.2%
- Target upside
- +79.1%
- High target gap
- +111.1%
- Target range width
- 96%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aquestive Therapeutics?
Aquestive Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $9.33.
How far are Aquestive Therapeutics's low and high targets from the recorded price?
The low target implies +15.2%, while the high target implies +111.1%.
How many analysts are included in Aquestive Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Aquestive Therapeutics's target upside or downside calculated?
The average target of $9.33 is divided by the recorded price of $5.21, then one is subtracted to produce +79.1%. This does not guarantee a future return.
When was Aquestive Therapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.